Table 2 clinical outcomes for all patients at pre and post therapy assessments and at 6-months follow up (N = 22)
mean (SD) | ESa (95% Confidence Intervall) | pb | ||
|---|---|---|---|---|
Outcomes | ||||
Number of symptoms (SOMS) | Pre | 18,50 (8,72) | ||
Post | 16,97 (9,41) | 0,17 (−0,19 - 0,52) | 0,40 | |
Follow up | 14,42 (8,01) | 0,48 (0,12 - 0,80) | 0,01 | |
Somatisation (PHQ-15) | Pre | 12,57 (4,86) | ||
Post | 10,87 (4,20) | 0,38 (0.06–0.70) | 0,03 | |
Follow up | 10,90 (5,13) | 0,33 (0.01–0.66) | 0,04 | |
Depression (PHQ-9) | Pre | 10,68 (3,96) | ||
Post | 9,06 (7,04) | 0,28 (−0,23 - 0,80) | 0,34 | |
Follow up | 9,18 (4,39) | 0,35 (−0,25–0.97) | 0,24 | |
Physical component scale (PCS; SF36) | Pre | 37,70 (11,59) | ||
Post | 37,03 (10,69) | 0,06 (−0,16–0.28) | 0,72 | |
Follow up | 37,67 (11,88) | 0,00 (−0,28–0.28) | 0,99 | |
Mental Component Scale (MCS; SF36) | Pre | 37,74 (9,28) | ||
Post | 43,00 (10,01) | 0,54 (0.13–0,96) | 0,02 | |
Follow up | 42,93 (9,88) | 0,52 (0.08–1,00) | 0,02 | |
DBIQ-35 Domains | ||||
Vitality | Pre | 2,57 (0,75) | ||
Post | 2,70 (0,85) | 0.16 (− 0,19 – 0,51) | 0.37 | |
Follow up | 2,78 (1,22) | 0.21 (−0,17 – 0,58) | 0.34 | |
Self-Acceptance | Pre | 3,04 (0,81) | ||
Post | 3,10 (0,73) | 0.09 (− 0,08 – 0,24) | 0.41 | |
Follow up | 3,24 (0,80) | 0.25 (0,06 – 0,44) | 0.04 | |
Sexuality | Pre | 2,98 (1,21) | ||
Post | 2,89 (1,10) | −0.07 (−0,30 – 0,14) | 0.64 | |
Follow up | 3,13 (1,49) | 0.11 (−0,18 – 0,40) | 0.78 | |
Self-Enhancement | Pre | 2,50 (0,84) | ||
Post | 2,50 (0,88) | 0.01(−0,19 – 0,21) | 0.96 | |
Follow up | 2,50 (0,89) | 0.01(−0,19 – 0,21) | 0.98 | |
Bodily contact | Pre | 3,34 (0,97) | ||
Post | 3,28 (1,21) | −0.06(−0,24 – 0,12) | 0.75 | |
Follow up | 3,27 (0,96) | −0.07(− 0,29 – 0,14) | 0.90 | |